Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial - Concepedia

Concepedia

Publication | Closed Access

Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial

190

Citations

17

References

2019

Year

Sonya Abraham, Helene Bæk Juel, Peter Fibiger Bang, Hannah M. Cheeseman, Rebecca Bach Dohn, Tom Cole, Max P Kristiansen, Karen Smith Korsholm, David Lewis, Anja Weinreich Olsen,

The Lancet Infectious Diseases

VaccinationMucosal VaccinationCaf01 LiposomesImmunologyAluminium HydroxideMedicineVaccine Research

References

	Year	Citations

Page 1